Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized first-line combination chemotherapy study in metastatic breast cancer
ISRCTN33132357Phase 3Completed
- Sponsor
- VU University Medical Center (Netherlands)
- Start
- Apr 2001
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Epirubicin + docetaxel, Vinorelbine + docetaxel and Epirubicin + vinorelbine (3 arms). Primary endpoints: Time to progression and Response rate. Started Apr 2001; status: completed.
02
Drugs
epirubicindocetaxelvinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN33132357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN33132357.